Object. Brain metastases are diagnosed in 20 to 40% of all cancer patients and are associated with a considerable drop in life expectancy and often also in quality of life for these patients. Several treatment options are available including surgery, chemotherapy, whole-brain radiotherapy, stereotactic radiotherapy, stereotactic radiosurgery, and Gamma Knife surgery (GKS). However, management of brain metastases still presents a challenge and there is no general consensus on the best treatment strategy. The aim of the authors' study was to further evaluate the efficacy of GKS in the treatment of brain metastases and to evaluate the predictive value of volumetric tumor follow-up measurement.
B
RAIN metastases are diagnosed in approximately 20 to 40% of all patients withcancer and thus represent the most common intracranial tumor. 28 The diagnosis of brain metastases is an indicator for a considerable decrease in life expectancy and QOL even for patients with controlled systemic cancer. To improve treatment strategies for these patients several studies have been performed to identify prognostic factors to assist in the deciding how aggressively a patient should be treated. 9, [10] [11] [12] 34, 36 Optimum management of these brain lesions still represents a challenge because treatment options are limited andthe Abbreviations used in this paper: GKS = Gamma Knife surgery; KPS = Karnofsky Performance Scale; MP-RAGE = magnetizationprepared rapid gradient echo; MR = magnetic resonance; QOL = quality of life; RRC = radiosurgery response classification; TV = tumor volume; TVR = TV reduction; WBRT = whole-brain radiotherapy; 3D = three-dimensional.
appearance of brain metastases varies considerably. Different primary cancers show different patterns of intracranial metastatic spread; however, not only the locations but the number of intracerebral metastases mainly depend on the type of primary cancer. Several treatment modalities for brain metastases have been developed over the last four decades, with the goal being to improve the local control of these tumors. However, QOL in patients with a life expectancy of only a few months is equally important as achieving prolonged survival. Metastatic brain lesions may be treated using several treatment modalities including resection, chemotherapy, WBRT, stereotactic radiotherapy, stereotactic radiosurgery, and GKS. A multimodal therapy is most commonly used. Even though refinements of available treatment modalities have achieved higher locoregional control of brain metastases, the overall survival of patients with metastatic brain lesions has not changed considerably over the past three decades. Treatment of brain metastases has many facets due to the wide range of primary tumors with varying chemo-and radiosensitivities. A review of literature showed that although some treatment guidelines 4, 7, 21, 26, 33 have been recommended, there is still no general consensus on the best treatment for patients with metastatic brain lesions. Based on published results of the effectiveness of GKS in local tumor control 13, 14, 20, 31 and prolonged good-quality survival, we chose to further explore the efficacy and limitations of GKS in the treatment of patients with brain metastases from various primary tumors. A special focus was set on TVR and its predictive value for survival and treatment outcome.
Clinical Material and Methods

Patient Population
In a prospective study consecutive patients with brain metastases from different radioresistant primary cancers underwent treatment between December 1998 and October 2005 at the Gamma Knife Center in Krefeld, Germany. Neurological deficits present on the day of GKS were defined as presenting symptoms and neurological symptoms documented at the last follow-up examination were defined as the neurological outcome. The KPS score rather than the number of metastases was used as an inclusion criterion for treatment. Patients with a KPS score below 70 due to uncontrolled systemic disease were not entered into this study. Exceptions to this inclusion criterion, however, were patients who had a KPS below 70 due to neurological dysfunction that was caused by the brain metastases that were planned for GKS treatment and who were expected to improve after GKS of the dysfunctionprovoking lesions.
Treatment and Follow-Up Protocol
All radiosurgical treatments were performed using a Leksell Gamma Knife Model C with APS. 16 To deliver a steep dose gradient to vulnerable surrounding structures and to reach a high conformity over irregular TV shapes, a maximum number of isocenters were applied in each case. 17 A T 1 -weighted 3D MP-RAGE contrast-enhanced MR imaging study was performed in all patients during each follow-up examination. Quantitative volumetric tumor analyses were conducted by two experienced neurosurgeons with either the Leksell GammaPlan V5.3 software or the CONVIS DICOM viewer software during each follow-up examination. If there was a difference in the measured TVs the maximum value was used for calculating TV changes. Our follow-up protocol included a first neuroradiological examination 6 to 9 weeks after GKS and every 3 months thereafter. A thorough neurological examination was performed during each follow-up examination. The KPS score was used to quantify general neurological impairment.
Imaging and Tumors
Imaging before GKS included T 1 -weighted contrastenhanced 3D MP-RAGE MR imaging and T 2 -weighted MR imaging to visualize edema surrounding a brain metastasis. A detailed quantitative volumetric tumor analysis was performed before GKS and during each followup examination. For the purpose of statistical analysis and grading, patients were subdivided in groups based on number of metastases (one brain metastasis, two-three brain metastases, four-six brain metastases, and Ͼ six brain metastases) TV and total treated TV (Ͻ2 cm 3 , 2 to Ͻ6 cm 3 , 6 to 10 cm 3 , and Ͼ 10 cm 3 ). The minimal detectable volume was 0.1 cm 3 . Treatment failure was defined as an increase in TV compared with the volume before GKS. Successful treatment was defined as a lack of tumor growth or a TVR.
Quantitative Volumetric Tumor Analysis
The quantitative volumetric tumor analysis was performed using contrast-enhanced MP-RAGE MR imaging and no overlap of the slices. In patients who underwent follow-up MR imaging at our center, we used an isotropic sequence that involved a square matrix of at least 256 but usually 512 pixels. In patients who underwent follow-up MR imaging at a different center, we required MR images with a minimal matrix resolution of 256-square pixels. Using these parameters, voxels between 0.5-and 1-mm edge length are acquired with approximately 4 to 5 cubic pixels resulting in a measurable and useful volume of 10 mm 3 . Using the surface areas of a tumor on each individual image, which was outlined by hand and knowing the thickness of each image slice (usually 1 mm), a quantitative TV calculation was made with either the Leksell GammaPlan, version 5.3, software or the CONVIS DI-COM viewer-based software.
The main difference between these programs relevant for the calculation of a TV is the calculation of the pixel size. The CONVIS DICOM viewer-based volume module uses the DICOM-header pixel information. The Leksell GammaPlan, version 5.3, software calculates the pixel size from the distance of the fiducials integrated in the localizer box of the Leksell stereotactic headframe and, by that means, acquires a more accurate pixel size. To ensure that the results measured by these two programs are comparable, we scanned spheres with a volume of 1 cm 3 filled with contrast medium and measured the volume using both programs. The results from serial measurements made on either system showed that the differences were less than 0.1 cm 3 and therefore not significantly different.
Volumetric Measurements
To ensure the quality of volumetric analysis in our center, we determined the error of segmentation. This was done by comparing real tumors with a volume of approximately 1 cm 3 . The volumes of these tumors were manually outlined by the two neurosurgeons performing all treatments and follow-up examinations in our center, and the results were analyzed. The maximum error in volumetric measurement of a 1-cm 3 volume was found to be 0.95 cm minimum and a maximum threshold value that can be determined by the user. Based on these values, one includes or excludes structures from the TV. The disadvantage in using such a filter is that, in the vicinity of the tumor, all contrast-enhancing isointense structures such as vessels are automatically included in the TV. For that reason, all images have to be corrected manually and this is just as time consuming as a complete manual segmentation. A possible improvement would be to use modelbased algorithms that automatically recognize anatomical structures and exclude them from the TV. However, to our knowledge, there are no segmentation algorithms available that are reliable enough to make a manual correction unnecessary.
Radiosurgery Response Classification
An RRC with three grades was used to describe TV changes after GKS ( Table 1 ). The three grades were defined according to the three possible TV changes observed after GKS. Radiosurgery response classification Grade I tumors are volume responders with shrinkage of TV greater than 10% after GKS; RRC Grade II tumors are treatment responders with unchanged TV after GKS; and RRC Grade III tumors are treatment nonresponders with TV growth greater than 10% after GKS. This new grading system classifies tumors according to their TV changes in response to GKS independent of their histological type and grade. Obviously the most important grade in this classification is Grade III because tumors classified as RRC Grade III need further treatment. The cutoff between the RRC grades is based on the quantitative TV analysis described above. Derived from the determined error in volumetric measurements previously described, a TV increase of more than 10% was defined as tumor growth and a reduction of TV of at least 10% was defined as a TVR. The RRC is currently used only as a descriptive classification with tumors being categorized according to the RRC at each follow-up examination independent of their follow-up interval.
Data Management and Statistical Analysis
The Leksell GammaPlan V5.3 was used for dose planning and TV analysis before GKS. The MeDigS Archive, version 1.1, was used to store and manage all clinical data and digital image data. The CONVIS DICOM viewer and GammaPlan were used during each follow-up examination for quantitative volumetric analysis. Microsoft Excel 2003 and SPSS, version 12.0, were used to perform statistical analyses and to plot graphs. Statistical tests included the Kaplan-Meier method, the log-rank statistic, the chisquare test, and the Mann-Whitney U-test. 
Results
Patients, Therapies, and Side Effects
Complete data in 300 patients (131 males, 169 females) were available for analysis (Table 2) ; the patients' mean age was 57.8 years (median 57.4 years, range 23.8-82.9 years). Patients were followed up during a mean period of 12.7 months (median 7.6 months, standard deviation 14.2). Brain metastases of the following cancers were treated: small cell lung cancer in 14 patients (4.7%), nonsmall cell lung cancer in 98 (32.7%), cancer of unknown primary in five (1.7%), uterine cancer in two (0.7%), colon cancer in 12 (4%), breast cancer in 73 (24.3%), malignant melanoma in 30 (10%), kidney cancer in 50 (16.7%), sarcoma in one (0.3%), and miscellaneous in 15 (5%). Before GKS microsurgical tumor resection was performed in 20 patients (6.7%), WBRT was conducted in 11 (3.7%), and chemotherapy alone was undertaken in 107 (35.7%). A total of 90 patients (30%) underwent a multimodal therapy before GKS; 13 patients (4.3%) underwent microsurgical tumor resection followed by WBRT, 22 patients (7.3%) underwent surgery followed by chemotherapy, and 24 patients (8%) underwent surgery, chemotherapy, and WBRT before GKS. Neurological examinations showed a mean KPS score of 79 before GKS and 78 at the end of the follow-up period. Symptomatic GKS-related side effects were observed in 27 patients (9%).
Tumors and Volume Reductions
A total of 703 brain metastases from various primary cancers were treated. Precocious presentation of brain metastases occurred in 12 patients (4%), a synchronous presentation of brain metastases occurred in 67 patients (22%), and in 221 patients (74%) the presentation of brain metastases was metachronous to the diagnosis of the primary cancer. Patients presented with a mean of three metastases (range one-18) ( Table 3 , Fig. 1) .
Analyses of TVs were performed quantitatively and according to the RRC described above. Analyzing the TV of brain metastases showed a mean volume of 2.1 cm 3 before and 1.1 cm 3 after GKS, which represents a statistically highly significant TVR (p Ͻ 0.0001). Treatments were performed using a mean prescription dose of 21.8 Gy (range 14-32.6 Gy; standard deviation 2.3) at a mean isodose of 50% applied over a mean of nine isocenters (range one-36; standard deviation 7.2). Analysis of the total treated TV (Fig. 2) showed a mean TV of 5.5 cm 3 (median 3.4 +/-6.2 cm 3 ). Analysis of the maximum prescription dose to the tumor peripheral dose demonstrated no statistically significant effect on TVR. The overall local tumor control rate was 84.5%. The quantitative volumetric TV analysis showed that in 79% of all treated metastases a mean TVR of 84.7% was achieved (Table 4 ). According to the RRC, 79% of all treated brain metastases in this study were Grade I, 5.5% were Grade II and 15.5% were Grade III. The results of TVR stratified by the RRC showed a mean TVR of 2.7 cm 3 for RRC Grade II tumors and a mean TV increase of 3.4 cm 3 for RRC Grade III tumors. 
Survival Analysis and Prognostic Factors
Overall Survival. The mean survival after the first diagnosis of systemic cancer was 49.1 months (median 35.4 months) and after diagnosis of the first brain metastasis it was 17.1 months (median 12 months).
Survival After GKS. The achieved mean overall survival (Table 4 , Fig. 3 ) after GKS was 13 months (median 8.3 months). The mean progression-free survival was 9.4 months (median 5.3 months). A total of 87 patients (29%) died during the follow-up period. When stratified by the RRC grade, the mean survival was length 7 months (median 2.7 months) for patients with Grade I tumors, 14.6 months (median 8.6 months) for patients with Grade II tumors, and 13.4 months (median 11 months) for patients with Grade III tumors.
Prognostic Factors. As potential predictive factors for outcome and survival, we analyzed the number of metastases at the time of GKS, total treated TV, and achieved TVR. Patients with a single brain metastasis had a statistically highly significant longer progression-free survival (p Ͻ 0.0001) and overall survival (p = 0.0005) than patients with multiple brain metastases (Figs. 4 and 5 ). Analysis of patients with multiple brain metastases showed a statistically significant longer progression-free survival and overall survival (p = 0.026) in those with a total TV of less then 1.5 cm 3 at the time of GKS regardless of the number of brain metastases (Fig. 6) .
Illustrative Case
This 41-year-old woman was diagnosed with breast cancer 3 years earlier. She underwent breast surgery and local radiotherapy. Two years later she developed lymph node metastases and underwent a second breast surgery and chemotherapy. Before diagnosis of these brain metastases in this case, the patient developed a paralysis of the left arm. The images in Fig. 7 left show the GKS treatment plan. The brain metastases with a total TV of 12.26 cm 3 were treated with 20 Gy to the 50% isodose line applied over 16 isocenters. Follow-up MR images (Fig. 7 right) 18 months later revealed that a total TVR of 11.79 cm 3 (96%) was achieved. The patient tolerated the treatment very well, and the paralysis of the left arm resolved completely. 
Discussion
Prognostic Factors and Treatment Paradigms
Brain metastases represent the most common type of intracranial tumors. 28 To determine the optimal treatment for patients and for better evaluation of treatment modalities, it is essential to have reliable prognostic factors. Numerous retrospective and prospective studies have been performed to identify pertinent prognostic factors for patients with brain metastases. Gasper, et al., 10 performed a retrospective study and introduced the recursion partitioning analysis classification to stratify patients into three different groups based on certain clinical characteristics. Several factors have been identified and confirmed in a randomized study in which the KPS score found to be the most important prognostic factor. 10, 12 Undoubtedly the KPS score is a significant prognostic factor and in the present study the majority of patients treated with GKS had a KPS score of 70 or higher. However, for patients with a KPS score below 70 a differentiation has to be made with regards to the reason why it is less than 70. We also included patients with a KPS score below 70 and found that survival of these patients was not statistically significantly different that in patients with a much higher KPS score. The reason for this is the fact that patients with a reduced KPS score were only included if the lesions planned for treatment with GKS were the only reason for a KPS below 70 rather than their systemic cancer. After successful treatment of these patients, the KPS score increased above 70 and in this way had no statistical effect on the mean survival.
Time of brain metastasis presentation has been described to be another important prognostic factor. Particularly for patients with non-small cell lung cancer, it was found that a synchronous presentation, 2 months within diagnosis of the primary tumor, is in most cases associated with poor survival. 9, 36 In this study 22% of patients had a synchronous presentation of brain metastases, 4% had a precocious tumor presentation, and 74% had a metachronous presentation of brain metastases. This distribution has previously been described in literature. 4 However, the time of presentation of a brain metastasis had no prognostic value in our study and there was no statistical difference in survival between these groups.
Approximately 30 to 40% of all patients with brain metastases develop only a single lesion 19 as is typically seen in patients with adenocarcinoma of the breast, colon carcinoma, renal cell carcinoma, and in patients with thyroid carcinoma. 6 Multiple brain metastases, on the other hand, are usually observed in patients with malignant melanomas 6 and in patients with lung cancer, which was found to be the leading source of brain metastases. 31 A similar distribution of metastatic spread to the brain was found in our group of patients as well. The number of brain metastases has been described as a predictor for survival, 4 with a higher number of brain metastases being generally associated with a shorter survival. For most of the recommended treatment paradigms the number of metastases is an important factor representing a junction between more aggressive and palliative treatments. 2, 7, 18 Our data are concordant with current literature in the fact that patients with a single brain metastasis had a statistically significant longer mean survival (p = 0.0005) than patients with multiple brain metastases. However, our results show that in patients with multiple brain metastases the total TV treated with GKS rather than the number of brain metastases had an influence on survival (p = 0.026) and could therefore serve as a prognostic factor. Patients with a TV of more than 1.5 cm 3 had a statistically significant shorter survival. Similar findings have been published by Metha, et al., 22 who showed that as tumor size increased control decreased. Based on our results, the TV before GKS could serve as a prognostic factor; however, further studies will be necessary to confirm this finding.
Even with all available prognostic factors it is still difficult to predict the course of disease for patients with brain metastases. Nevertheless, predictive factors are central because they present a guide in the decision-making process on how aggressively to treat patients, especially those with decreased QOL and considerably reduced life expectancy.
Tumor Volume Reduction After GKS
A review of literature by Prasad 27 showed that the median survival of patients with brain metastases varied greatly in different series depending on the different tumor types but rarely exceeded 12 months regardless of the treatment modality used. The overall median survival of patients in this study was at 8.3 months and is concordant with literature. The high efficacy of GKS in the treatment of brain metastases especially compared with WBRT has been previously described. 23, 25 Reported local tumor control rates range from 82 to 100%, and also TVRs of brain metastases have previously been shown. 3, 23, 29, 32 Even patients with multiple brain metastases were treated successfully with GKS. 15, 18, 23, 24, 35 Local tumor control rates after GKS were comparable to results of surgical treatment, however, with a much lower morbidity and no mortalities. Undoubtedly microsurgical treatment is essential in cases in which it is necessary to achieve an immediate decompression of neurovascular structures. Results of this study are in accordance with literature, with a local tumor control rate of 84.5% and a morbidity of only 7.3%.
Even though TVRs after GKS have been reported, quantitative volumetric analyses are rarely performed because they are time consuming. It has previously been reported that tumor size has an influence on the therapeutic ratio 19 and it was also shown that the maximum tolerated radiosurgery dose is directly related to tumor size. 30 However, there are few reports on the impact of reduced TV on survival after GKS. With the purpose of analyzing the predictive value of TVR on survival, a quantitative volumetric tumor analysis was performed. To define volume changes more precisely and to make results more comparable in the future, we used the RRC (Table 1) to describe TV changes. This classification is currently used as a descriptive classification, but further studies and genetic tumor analysis might change the RRC to a predictive classification in the future. According to the RRC, a mean TVR of 84.7% was achieved in 79% of all treated metastases in this study. These results are very encouraging in terms of local tumor control. However, statistical analysis showed that there was no correlation between the achieved TVR and survival of a patient after GKS, and stratification of results by the RRC showed that patients with RRC Grade I tumors had a shorter survival than those with RRC Grade III tumors.
Even though our results were encouraging, we found that the time-consuming process of quantitative volumetric tumor analysis did not prove to be as valuable for patients with brain metastases as it has previously been shown for patients with benign tumors. 8 These results show once more that good local tumor control and even TVR do not automatically translate to better survival. If good local tumor control does not have an effect on survival, what will? In our view, more studies should be performed with the focus on one type of systemic cancer and its metastatic behavior rather than evaluating several different types of brain metastases from various primary cancers simultaneously. It seems that with the currently available treatment modalities the maximum possible survival rates have been reached and that only after improvement of systemic treatment will further progress in survival and QOL for patients with brain metastases be possible. The combination of early radiosurgery treatment and aggressive treatment of the systemic cancer can potentially improve not only QOL but possibly even improve survival rates. Nonetheless, of all the available treatment modalities, GKS remains an efficient treatment option with a low associated morbidity rate and essentially no death, and furthermore it has even been shown to be effective for tumors unresponsive to WBRT.
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Conclusions
Gamma Knife surgery is a safe and effective treatment for patients with brain metastases regardless of the previous treatment and histological tumor type. The results in literature and in the present study show that local tumor control and TVRs are comparable to microsurgical tumor resection but with a much lower morbidity rate and essentially no mortality. An RRC was used to set a standard for quantitative volumetric tumor analysis and to make TVR results of studies using GKS better comparable in the future. The extent of achieved TVR was not an indicator of survival and can therefore not be used as a prognostic factor. The time-consuming process of quantitative volumetric follow up has therefore proven to be of less value for brain metastases as it is for benign tumors; however, results of this study show that it is not the number of brain metastases but rather the total TV treated with GKS that may have a prognostic value for survival of patients with brain metastases. Further studies will be necessary to confirm this finding. Based on findings in literature and this study, GKS should also be considered as a primary treatment option for patients with brain metastases even in cases of multiple metastases.
